|NeuroVive Pharmaceutical AB -- Sweden Stock|| |
SEK 3.23 0.07 2.12%
Chief Scientific Officer
Mr. Eskil Elmer has served as Chief Scientific Officer at NeuroVive Pharmaceutical AB since 2000. He was Member of the Company Board of Directors from May 2010 until June 8, 2012. Previously, he acted as the Company Chief Executive Officer from 2007 until May 2010, and he also served on the Company Board of Directors between 2000 and 2008. Eskil Elmer is Physician and Associate Professor of experimental neurology. He holds Medical degree and Doctorate of Philosophy degree from Lunds universitet. He is one of the Founders of the Company. He serves as Board member of Maas Biolab LLC and Restorative Neurosurgery Foundation .
Age: 45 Executive Since 2012 Ph.D
46 4 62 75 62 20 http://www.neurovive.com
The company has return on total asset (ROA)
of (15.32) %
which means that it has lost $15.32 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (47.87) %
meaning that it generated substantial loss on money invested by shareholders.
NeuroVive Pharmaceutical AB engages in the research, discovery, and development of mitochondrialprotecting pharmaceuticals in Sweden and Hong Kong. NeuroVive Pharmaceutical AB (NVP) is traded on Stockholm Stock Exchange in Sweden. It is located in Lund, and employs 15 people.